Abstract
To study the efficacy and safety of intranasal administration of 5 mg haloperidol on mild-moderate agitated patients with schizophrenia or schizoaffective disorder in an acute psychiatry unit setting.
MeSH terms
-
Administration, Intranasal
-
Antipsychotic Agents / adverse effects
-
Antipsychotic Agents / therapeutic use*
-
Benzodiazepines / therapeutic use
-
Haloperidol / adverse effects
-
Haloperidol / therapeutic use*
-
Humans
-
Pilot Projects
-
Psychiatry*
-
Psychomotor Agitation / drug therapy
-
Schizophrenia* / drug therapy
-
Treatment Outcome
Substances
-
Antipsychotic Agents
-
Benzodiazepines
-
Haloperidol